View More
Outcomes are poor for patients with myelofibrosis who discontinue ruxolitinib due to loss of response or intolerance. In this commentary, I offer my thoughts on the best treatment options for these patients.
Srdan Verstovsek, MD, PhD
Released: October 7, 2019
In this commentary, Raajit K. Rampal, MD, PhD, highlights key MPN studies that will be presented at the upcoming 2019 ASH annual meeting in Orlando.
Raajit K. Rampal, MD, PhD
Released: December 2, 2019
Read expert answers to key questions from the audience at a recent symposium on optimal management of patients with myeloproliferative neoplasms.
Srdan Verstovsek, MD, PhD
Jean-Jacques Kiladjian, MD, PhD
Raajit K. Rampal, MD, PhD
Alessandro M. Vannucchi, MD
Released: January 16, 2020
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.